Molecular Partners doses first patients in Phase 2 MP0317 combo trial for cholangiocarcinoma

(AWP Alliance News) - Molecular Partners reported first patients have been dosed in an investigator-initiated, randomized Phase 2 study testing MP0317 with standard chemoimmunotherapy as a first-line treatment for advanced cholangiocarcinoma. The trial is designed to evaluate whether adding MP0317 can improve patient outcomes versus standard of care alone.

No efficacy results have been presented yet. A trial-in-progress poster is scheduled for ESMO 2026 in October, with a data update expected in 2027 and study completion targeted for 2028.

https://www.sec.gov/Archives/edgar/data/1745114/0001171843-26-004758-in…

Disclaimer: This news brief was created using generative artificial intelligence. Molecular Partners AG published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission, on July 20, 2026, and is solely responsible for the information contained therein.